Maryland Heights, MO, February 21, 2017 --(PR.com
)-- The global exocrine pancreatic insufficiency diagnostics market to reach nearly USD 2.3 Billion in 2020, at a CAGR of 8.9% from 2016 to 2020.
Browse Exocrine Pancreatic Insufficiency Diagnostics Market by Diagnostic Test Types (Blood Tests, Endoscopic Ultra-Sonography, Magnetic Resonance Imaging, Computer Tomography Scanning) 2016-2020 report at https://www.ihealthcareanalyst.com/report/exocrine-pancreatic-insufficiency-diagnostics-market/.
Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of the exocrine pancreatic enzymes. This results in the inability to digest food properly or maldigestion. These enzymes consist of lipases, proteases and amylases. These enzymes primarily consist of lipases for fat digestion, proteases for protein digestion, and amylases for starch digestion. EPI results from various diseases such as cystic fibrosis, chronic pancreatitis, pancreatic cancer, cytomegalovirus infection, and HIV/AIDS. The pancreatic enzyme products (PEPs) used for PERT are extracts of porcine pancreas that contain all 3 pancreatic enzymes such as amylase, protease, and lipase in varying proportions. A complete laboratory evaluation including pancreatic function testing is required to diagnose EPI and to determine the extent of the malabsorption.
The global exocrine pancreatic insufficiency diagnostics market segmentation is based on diagnostic test types (blood tests, endoscopic ultra-sonography, magnetic resonance imaging, Computer Tomography scanning). The global exocrine pancreatic insufficiency diagnostics market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020). The global exocrine pancreatic insufficiency diagnostics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global exocrine pancreatic insufficiency diagnostics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global exocrine pancreatic insufficiency diagnostics market and included in this report are AbbVie, Inc., Nordmark Arzneimittel GmbH & Co. KG, Allergan Plc., Digestive Care, Inc., Janssen Pharmaceuticals, Inc., and others.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/exocrine-pancreatic-insufficiency-diagnostics-market/.
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
2109, Mckelvey Hill Drive
Maryland Heights, MO 63043